Evidence check: Pharmakogenetik Medicheck in the context of Haut

The query concerns a 'Pharmacogenetics Medicheck' in the context of skin. Pharmacogenetics studies how genetic variants affect drug response and safety. In dermatology, there are some established applications, such as testing for HLA-B*5701 before abacavir or TPMT variants before azathioprine. However, most commercial DNA tests marketed for skin issues like wrinkles, collagen, or glycation lack solid scientific backing. The provided context consistently rates such tests as marketing/unclear. There are no robust studies showing that a direct-to-consumer test improves choice of skincare or diet for skin aging. The evidence for pharmacogenetic testing in dermatology is mixed: for some drugs (e.g., allopurinol, carbamazepine) there are strong HLA associations, but these are specific and not part of general 'skin health' tests. A 'Medicheck' for skin without a specific medication context is therefore misleading. Consumers should focus on proven lifestyle factors (UV protection, diet) and seek medical advice for specific drug-related questions. The evidence for such broad tests is weak to nonexistent.